title: Reversal of a dabigatran overdose: what are possible options?
authors: Supawat
authors: S
authors: Ratanapo
authors: Patompong
authors: P
authors: Ungprasert
authors: Narat
authors: N
authors: Srivali
authors: Wisit
authors: W
authors: Cheungpasitporn
authors: Edward F
authors: EF
authors: Bischof
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D003029:Coagulants / Q000627:therapeutic use; D000069604:Dabigatran; D015942:Factor VIIa / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D011516:Prothrombin / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D003029:Coagulants; D011994:Recombinant Proteins; D015091:beta-Alanine; D011516:Prothrombin; C103587:recombinant FVIIa; D015942:Factor VIIa; D000069604:Dabigatran